Source disclosure: February 10, 2026
KOBAYASHI PHARMACEUTICAL CO.,LTD. [4967.T]
TOKYO, Feb 10 (Pulse News Wire) – Kobayashi Pharmaceutical CO.,LTD. (4967.T) resolved at its February 10 board meeting to transition from an audit committee firm to an audit and supervisory committee firm, contingent upon shareholder approval at the scheduled March 27 annual general meeting.
The move follows the company's commitment to fundamental corporate governance reform outlined in its December 17 press release addressing preventive measures for issues related to its red yeast rice products. The restructuring aims to enhance oversight mechanisms by separating management functions and improving decision-making efficiency through delegated authority from the board to individual directors. The company plans to implement these changes after obtaining necessary approvals at the upcoming annual general meeting.
Post-transition personnel appointments will be detailed in a separate announcement released today. Further updates on the amendments to the articles of incorporation will be communicated once finalized.
AI-translated content. 🟢 Confidence: High See terms • Original filing